Veterinary medicines: product update
The following information has been produced for Veterinary Record by the Veterinary Medicines Directorate (VMD) to provide an update for veterinary surgeons on recent changes to marketing authorisations for veterinary medicines in the UK and other relevant issues.
THE points below highlight changes in marketing authorisations that may have a significant impact on veterinary surgeons' prescribing decisions.
New marketing authorisations
New marketing authorisations that were issued in November 2011 are listed in Table 1. Of the products authorised in this period, none contains an active ingredient not previously included in an authorised veterinary medicinal product in the UK.
- In this window
- In a new window
Marketing authorisations issued in November 2011
These products may not yet be readily available in the UK. Veterinary surgeons should contact the marketing authorisation holder directly for details of supply.
Table 1 also indicates where a public assessment report should become available for a product on the VMD's website. Where available, links to these reports are accessible by clicking on the relevant product in the VMD's Product Information Database, www.vmd.defra.gov.uk/ProductInformationDatabase/
The European Medicines Agency (EMA) publishes European Public Assessment Reports (EPARs) for every veterinary medicine that is authorised through a centralised procedure. Links to these reports are accessible on www.ema.europa.eu
Marketing authorisation variations
The following clinically significant variations to marketing authorisations were approved and/or published during November 2011:
■ Bexepril 2.5 mg, 5 mg and 20 mg film-coated tablets for dogs.
Change of invented name to ‘Forzepril 2.5 mg, 5 mg and 20 mg film-coated tablets for dogs’.
■ Clavoral 500/125 mg tablets for dogs, 50/12.5 mg tablets for cats and …
